Focusing on the tumor suppressor gene PTEN, the researchers created a mouse model system to study tumor progression in prostate cancer. PTEN is among the most commonly mutated tumor suppressor ...

Therefore, we asked if reconstitution of PTEN function would lead to the reversal of resistance to apoptosis in prostate cancer cells. Adenovirus-mediated expression of PTEN completely suppressed ...

In addition, both cytoplasmic and nuclear PTEN are independently associated with good outcome measures in hormone-sensitive prostate cancer, but appear to have independent roles.

PTEN's role in prostate cancer has been relatively well characterized in mouse models that faithfully mimic human disease. These models, several of which had been previously developed by the study ...

"Loss of the tumor suppressor PTEN due to mutation or deletion not only is frequent in human prostate cancer, but also plays a large role in other cancers. We wanted to find out more about PTEN ...

A gene called Pten, which codes for a tumour-suppressing enzyme, is inactive in the majority of advanced prostate cancer patients. The team used a technique called single-cell RNA sequencing to ...

Tindall, Ph.D., editorial board member of Cancer Research. “The significance of these findings is the demonstration that a subpopulation of prostate cells from Pten null mice has the capability ...

Notably, the ARCHES trial had the longest median follow-up among ARPI trials at 61.4 months. During this period, median overall survival was not reached in either treatment arm. At 5 years, 66% (two ...

Veracyte, Inc. (NASDAQ:VCYT) announced that eight new studies featuring its Decipher Prostate and Decipher Bladder genomic ...

The results will likely have a significant impact as PTEN gene mutation effects reach far beyond breast cancer and are heavily linked to uterus, skin, prostate, thyroid, and kidney cancers.

Truqap with Zytiga and ADT improved radiographic progression-free survival in patients with PTEN-deficient prostate cancer compared to placebo. The CAPitello-281 trial involved 1,012 patients, showing ...

UK-based pharmaceutical company AstraZeneca has reported positive results from its Phase III CAPItello-281 trial, which evaluated Truqap combined with abiraterone and androgen deprivation therapy ...